



Press release

Stockholm, June 22, 2021

CytaCoat announces appointment of Graeme Brookes as CEO

CytaCoat AB, developers of the unique CytaCoat anti-microbial coating technology, have appointed Graeme Brookes as Chief Executive Officer.

Graeme's appointment further strengthens the capabilities of the management team and provides increased emphasis on implementing this promising technology into clinical use. A key focus for Graeme will be the development, clinical, regulatory and reimbursement strategies necessary to underpin the commercial potential of the CytaCoat technology. He will also focus on the business development and commercial actions needed to develop licensing agreements and revenues via relationships with key strategic go-to-market partners.

Graeme was previously CEO at Reaplix A/S in Denmark for six years taking a blood derived cell and growth factor device-based therapy through development, EU and US regulatory clearances, clinical trial completion (published in The Lancet) and high-level US reimbursement. He has also held senior roles at Stanmore Implants, Acrobot, Advanced Medical Solutions plc and Johnson and Johnson.

The appointment of Graeme to the role of CEO sees Per Wirsén move to the role of Chairman and Nina Rawal becomes non-executive director.

Per Wirsén, now appointed as Chairman of CytaCoat AB, said:

"We are very pleased to welcome Graeme to CytaCoat at this important time in the development of the company. Graeme has very relevant experience that can be applied to the next defining stages as we execute our future strategies to ensure that we build on the significant progress to date. As part of this change, we would like to thank Nina Rawal for her work as Chairman, helping us to continually build momentum and drive the company forward".

FURTHER INFORMATION:

GRAEME BROOKES, CEO
+44 7572425331
graeme.brookes@cytacoat.se

PER WIRSÉN, CHAIRMAN
+33 665467550
per.wirsen@cytacoat.se

ABOUT CYTACOAT

CytaCoat AB is a privately held company based at the Karolinska Institute Science Park with a strong Swedish investor base, including Segulah Medical Acceleration. The company has developed the CytaCoat anti-microbial coating for medical devices, with the objective of preventing healthcare-associated infections, one of the biggest problems in healthcare today. An effective anti-microbial coating can destroy or inhibit the growth of microorganisms, including bacteria, fungi and viruses.

CytaCoat's anti-microbial coating contains only non-toxic, biocompatible organic components and has been successfully applied to many materials used in the medical device industry. The company is now moving forward from lab scale coating development and technology optimization to build a pilot coating plant, which will support the manufacturing of coated devices for clinical evaluations. The company aims to license the technology to leading, established medical device players for multiple application-specific devices.

See www.cytacoat.com